MA44085A - Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants - Google Patents
Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendantsInfo
- Publication number
- MA44085A MA44085A MA044085A MA44085A MA44085A MA 44085 A MA44085 A MA 44085A MA 044085 A MA044085 A MA 044085A MA 44085 A MA44085 A MA 44085A MA 44085 A MA44085 A MA 44085A
- Authority
- MA
- Morocco
- Prior art keywords
- diamino
- alkylamino
- bonded
- voltage
- sodium channels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562269648P | 2015-12-18 | 2015-12-18 | |
US201662417040P | 2016-11-03 | 2016-11-03 | |
US201662422182P | 2016-11-15 | 2016-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44085A true MA44085A (fr) | 2021-04-21 |
Family
ID=59057567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA044085A MA44085A (fr) | 2015-12-18 | 2016-12-15 | Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants |
Country Status (10)
Country | Link |
---|---|
US (1) | US10519147B2 (fr) |
EP (1) | EP3389654B1 (fr) |
JP (1) | JP2019502688A (fr) |
KR (1) | KR20180096683A (fr) |
CN (1) | CN109069489A (fr) |
AU (1) | AU2016370677A1 (fr) |
BR (1) | BR112018012408A2 (fr) |
CA (1) | CA3008614A1 (fr) |
MA (1) | MA44085A (fr) |
WO (1) | WO2017106409A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3390374B1 (fr) | 2015-12-18 | 2020-08-26 | Merck Sharp & Dohme Corp. | Composés diamine-arylsulfonamide à substitution hydroxyalkylamine et hydroxycycloalkylamine avec activité sélective des canaux sodiques sensibles à la tension |
US10442778B2 (en) | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
RU2769827C2 (ru) | 2016-05-20 | 2022-04-06 | Ксенон Фармасьютикалз Инк. | Соединения бензолсульфонамида и их применение в качестве терапевтических средств |
SG11201903348UA (en) | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
ES2897998T3 (es) * | 2016-10-27 | 2022-03-03 | Bristol Myers Squibb Co | Inhibidores de la acilsulfonamida del NaV1.7 |
WO2018093694A1 (fr) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Composés d'arylsulfonamide à liaisons diamino-alkylamino présentant une activité sélective dans les canaux sodiques sensibles à la tension |
US20180162868A1 (en) | 2016-12-09 | 2018-06-14 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
EP3601273B1 (fr) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | Dérivés de 4-pipéridine-n-(pyrimidin-4-yl) chromane-7-sulfonamide en tant qu'inhibiteurs de canaux sodiques |
JP2021514980A (ja) | 2018-02-26 | 2021-06-17 | ジェネンテック, インコーポレイテッド | 疼痛及び関連病態に対するピリジン−スルホンアミド化合物及びその使用 |
JP2021519788A (ja) | 2018-03-30 | 2021-08-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物 |
TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
SG11202011862PA (en) | 2018-06-13 | 2020-12-30 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
EP3844150A1 (fr) | 2018-08-31 | 2021-07-07 | Xenon Pharmaceuticals Inc. | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques |
US10752623B2 (en) | 2018-08-31 | 2020-08-25 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
US12246008B2 (en) * | 2018-12-05 | 2025-03-11 | Merck Sharp & Dohme Llc | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels |
CN117362206B (zh) * | 2023-12-08 | 2024-02-20 | 四川大学华西第二医院 | 一类芳基磺酰胺类化合物、合成方法及用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202861B2 (en) * | 2003-08-08 | 2012-06-19 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
CL2008000835A1 (es) | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
WO2010079443A1 (fr) * | 2009-01-12 | 2010-07-15 | Pfizer Limited | Dérivés sulfonamides |
US20170275275A1 (en) | 2014-05-30 | 2017-09-28 | Pfizer Inc. | Benzenesulfonamides useful as sodium channel inhibitors |
WO2016009303A1 (fr) | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Associations de produits pharmaceutiques comprenant de la gabapentine ou de la prégabaline avec des inhibiteurs de nav1.7 |
EP3390374B1 (fr) * | 2015-12-18 | 2020-08-26 | Merck Sharp & Dohme Corp. | Composés diamine-arylsulfonamide à substitution hydroxyalkylamine et hydroxycycloalkylamine avec activité sélective des canaux sodiques sensibles à la tension |
WO2018093694A1 (fr) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Composés d'arylsulfonamide à liaisons diamino-alkylamino présentant une activité sélective dans les canaux sodiques sensibles à la tension |
-
2016
- 2016-12-15 MA MA044085A patent/MA44085A/fr unknown
- 2016-12-15 BR BR112018012408A patent/BR112018012408A2/pt not_active Application Discontinuation
- 2016-12-15 WO PCT/US2016/066765 patent/WO2017106409A1/fr active Application Filing
- 2016-12-15 KR KR1020187020096A patent/KR20180096683A/ko unknown
- 2016-12-15 JP JP2018531237A patent/JP2019502688A/ja active Pending
- 2016-12-15 US US16/061,815 patent/US10519147B2/en active Active
- 2016-12-15 EP EP16876635.0A patent/EP3389654B1/fr active Active
- 2016-12-15 CA CA3008614A patent/CA3008614A1/fr not_active Abandoned
- 2016-12-15 CN CN201680081253.3A patent/CN109069489A/zh active Pending
- 2016-12-15 AU AU2016370677A patent/AU2016370677A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112018012408A2 (pt) | 2018-12-04 |
EP3389654B1 (fr) | 2023-08-16 |
CN109069489A (zh) | 2018-12-21 |
EP3389654A1 (fr) | 2018-10-24 |
US20180362518A1 (en) | 2018-12-20 |
US10519147B2 (en) | 2019-12-31 |
KR20180096683A (ko) | 2018-08-29 |
AU2016370677A1 (en) | 2018-06-07 |
CA3008614A1 (fr) | 2017-06-22 |
JP2019502688A (ja) | 2019-01-31 |
WO2017106409A1 (fr) | 2017-06-22 |
EP3389654A4 (fr) | 2019-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44085A (fr) | Composés d'arylsulfonamide à liaisons diamino-alkylamino ayant une activité sélective vis-à-vis des canaux sodiques voltage-dépendants | |
EP3720430A4 (fr) | Composés benzocarbonyle | |
EP3737672A4 (fr) | Composés benzamide | |
MA56008A (fr) | Composés et compositions pour traiter des états associés à une activité de nlrp | |
EP3408292A4 (fr) | Intéines clivées à activité d'épissage exceptionnelle | |
MA42293A (fr) | Composés antibactériens | |
EP2770995A4 (fr) | Composés de benzoxazolinone ayant une activité sélective dans des canaux sodiques voltage-dépendants | |
EP3484464A4 (fr) | Composés de n1-phénylpropane-1,2-diamine ayant une activité sélective dans des canaux sodiques sensibles à la tension | |
MA41614A (fr) | Composés antiviraux | |
EP2911668A4 (fr) | Composés benzoxazolinone ayant une activité sélective dans les canaux sodiques potentiel-dépendants | |
EP2964221A4 (fr) | Composés inhibant l'activité enzymatique de la kinase à répétition riche en leucine | |
DK3222650T3 (da) | Dispergeringsmiddel | |
EP2964222A4 (fr) | Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine | |
MA43155A (fr) | Composition de déblocage de nez congestionné présentant une activité antivirale | |
EP2964220A4 (fr) | Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine | |
EP3340844A4 (fr) | Mélangeur personnel amélioré | |
DK3337795T3 (da) | Piperidinobenzodiazepinforbindelser med anti-proliferativ aktivitet | |
MA41169A (fr) | Composés antibactériens à large spectre d'activité | |
EP3250230A4 (fr) | Modulateurs d'activité du complément | |
EP3464336A4 (fr) | Composés | |
EP2983677A4 (fr) | Composés photosensibles | |
EP3261631A4 (fr) | Inhibition de l'activité d'olig2 | |
EP3310352A4 (fr) | Composés cristallins | |
EP3405231A4 (fr) | Connecteurs à usage unique | |
EP3259254A4 (fr) | Composés thérapeutiques |